Louisiana Funds

Founded in 2011, Qure4u develops a comprehensive patient engagement platform that connects patients, doctors, labs, pharmacies, and insurance carriers. The platform aggregates vital information such as diagnoses, allergies, medications, lab results, vitals, and appointments, providing immediate access to enhance clinical insight and improve patient experience.

Omnidek is an enterprise smart data content management platform that provides businesses of all sizes with tools to create corporate forms, portals, workflows, and analytics within a unified mobile and web interface. The platform aims to streamline operations by eliminating the need for paper, files, and spreadsheets, thereby enhancing efficiency and organization. It features a chat-style inbox that integrates messaging with workflows, simplifying communication and collaboration among teams. By consolidating third-party applications, Omnidek offers an ecosystem that facilitates the seamless rollout of technology across organizations, enabling data-driven decision-making and smart insights for improved business processes.

Servato Corp., established in 2014 and headquartered in New Orleans, Louisiana, specializes in active battery management solutions for various industries, including telecom, data centers, utilities, and industrials. The company offers an Active Battery Management System, a solution for managing, charging, and monitoring lead-acid batteries used in industrial backup power settings. Additionally, Servato provides the Smart Power System-148, a remote management appliance, and ActiView, an analytics-driven battery management software, enabling users to monitor and understand the health of batteries across different sites.

Embera NeuroTherapeutics, Inc. is a pharmaceutical company based in Sudbury, Massachusetts, founded in 2005. The company is focused on developing innovative treatments for smoking cessation, cocaine dependence, and other addictions, an area where effective drug therapies are limited or nonexistent. Embera's flagship product, EMB-001, combines the benzodiazepine oxazepam with metyrapone, a cortisol synthesis inhibitor, to target the stress response system and specific brain functions linked to cravings and relapse. This dual-action approach aims to modulate various stress-related pathways, thereby reducing the cravings that drive addictive behaviors. By addressing the underlying mechanisms of addiction, Embera NeuroTherapeutics seeks to offer a more effective solution for individuals struggling with these disorders.

Embera NeuroTherapeutics, Inc. is a pharmaceutical company based in Sudbury, Massachusetts, founded in 2005. The company is focused on developing innovative treatments for smoking cessation, cocaine dependence, and other addictions, an area where effective drug therapies are limited or nonexistent. Embera's flagship product, EMB-001, combines the benzodiazepine oxazepam with metyrapone, a cortisol synthesis inhibitor, to target the stress response system and specific brain functions linked to cravings and relapse. This dual-action approach aims to modulate various stress-related pathways, thereby reducing the cravings that drive addictive behaviors. By addressing the underlying mechanisms of addiction, Embera NeuroTherapeutics seeks to offer a more effective solution for individuals struggling with these disorders.

Esperance Pharmaceuticals Inc. is a biotechnology company focused on developing targeted anticancer drugs aimed primarily at treating ovarian and breast cancer in women. Founded in 2005 and based in Houston, Texas, the company is advancing its lead product, EP-100, an oncolytic peptide designed to selectively attack and destroy cancer cells that express luteinizing hormone releasing hormone (LHRH) receptors. This innovative approach enables the drug to kill cancer cells, including those resistant to traditional chemotherapeutics, while sparing normal cells. Esperance Pharmaceuticals has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, enhancing its potential impact in oncology.

Esperance Pharmaceuticals Inc. is a biotechnology company focused on developing targeted anticancer drugs aimed primarily at treating ovarian and breast cancer in women. Founded in 2005 and based in Houston, Texas, the company is advancing its lead product, EP-100, an oncolytic peptide designed to selectively attack and destroy cancer cells that express luteinizing hormone releasing hormone (LHRH) receptors. This innovative approach enables the drug to kill cancer cells, including those resistant to traditional chemotherapeutics, while sparing normal cells. Esperance Pharmaceuticals has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, enhancing its potential impact in oncology.

At Portico, they have focused on providing eLearning solutions to government and corporate entities since 1998. They specialize in courseware management and custom eLearning courseware development, and have implemented both their courseware and their learning management systems successfully in a wide range of technical environments. Their company currently provides eLearning to many companies spanning many industries, worldwide. Their approach to every solution is to match training initiatives to their clients' business objectives and strategies, enabling them to add value to their enterprise.

Founded in 1986, Dowley Security Systems specializes in designing, installing, monitoring, and maintaining electronic security solutions for critical infrastructure, education, government, and commercial markets. Its comprehensive services include access control, video surveillance, intrusion detection, perimeter security, information management, security networking, maintenance, and service support.

Flying Fish Creative Services is a commercial art studio. offering illustration, design, retouching, digital imaging, and photographic services. They focused on courseware management. They delivers creative solutions to small businesses, corporate clients and local non-profits.

Primorigen Biosciences Inc. is a biotechnology company based in Madison, Wisconsin, founded in 2005. The company specializes in the development of innovative protein and cell-based assay systems aimed at cellular characterization and preclinical research. Its product offerings include cell culture matrices, antibodies, recombinant proteins, primary neuronal cells, and mesenchymal stem cells. Primorigen Biosciences focuses on providing efficient and cost-effective solutions for stem cell maintenance, proliferation, differentiation, and large-scale production, catering to the needs of researchers and organizations in the life sciences sector. As of August 2019, it operates as a subsidiary of Nucleus Biologics.